| HOME >> MEDICINE >> TECHNOLOGY |
(4) Parker C, Omine M, Richards S, et al. Diagnosis and management of
paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699-3709.
(5) Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor
and distribution-based methods to derive minimal clinically important
differences on the Functional Assessment of Cancer Therapy (FACT)
anemia and fatigue scales. J Pain Symptom Manage 2002 Dec;24(6):547-
61.
(6) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of
paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in
Yorkshire [abstract]. Blood. 2006;108(11):985.
(7) Socie G, Mary J Yves, de Gramont A, et al. Paroxysmal nocturnal
haemoglobinuria: long-term follow-up and prognostic factors. Lancet
1996; 348:573-577.
(8) Johnson RJ, Hillmen P. Paroxysmal nocturnal hemoglobinemia: Nature's
gene therapy? J Clin Path: Mol Pathol. 2002;55:145-152.
(9) Wang, et al. Clinical significance of a minor population of
paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure
syndrome. Blood 2002;100:3897-3902.
(10) Iwanga, et al. Paroxysmal nocturnal haemoglobinuria clones in
patients with myelodysplastic syndromes. Brit J Haem. 1998; 102:465-
474.
(11) Maciejewski, et al. Relationship between bone marrow failure
syndromes and the presence of glycophosphatidyl inositol-anchored
protein-deficient clones. Brit J Haem. 2001;115:1015-1022.
(12) Hill A, Richards S, Hillmen P. Recent developments in the
understanding and management of paroxysmal nocturnal haemoglobinuria.
British Journal of Haematology 2007; 137:3, 181-192.
| SOURCE Alexion Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |